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Instructions
Please review the following vignette carefully and answer the three questions following the vignette. In your review of this vignette, please assume that the design and methods of the study are scientifically sound and appropriate, even though they are not described in detail. Do not focus on providing criticism of information that is lacking (i.e., sample size, inclusion criteria) [P1]. Instead, consider the overall description of the study. Please remember that as an Institutional Review Board member, you have a responsibility to both participants in the study and people who may later be given the treatment being tested if it is found to be safe and effective. We refer to people who may get the treatment at a later time as "future patients." Some health care providers have been using Treatment X off label to treat patients with metastatic pancreatic cancer. Treatment X is not approved by the Food and Drug Administration (FDA) for the treatment of metastatic pancreatic cancer. Doctors are uncertain which of these two treatments is the most effective and the least toxic. If either drug fails to treat a patient's metastatic pancreatic cancer the patient will most certainly die [P6].
A group of investigators have submitted a proposal to your Institutional Review Board proposing a randomized controlled trial (RCT) testing whether treatment X is better than treatment Y in improving patients' survival [P7]. That is, their goal is to learn which of these two treatments improves survival [P8] better under the ideal conditions of a research study and not necessarily [P9] in a real medical practice. The proposed trial is a well-designed RCT in which treatment assignment is determined by chance (random assignment). In other words, there is a 50% [P10] chance of patients receiving Treatment X versus Treatment Y. The enrolled participants will be advised to follow the study treatment protocol, which will require stopping all concurrent metastatic pancreatic cancer treatment(s) upon initiation of the study. The RCT targets 40-60 year old adult patients.
The results of a survey of 100 leading experts on metastatic pancreatic cancer are available to you. Adherence to protocol 2 levels (strict protocol-based schedule vs. no requirement for stoppage of standard therapy)
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